Roche Holding Ag Stock News

Imugene Ltd (ASX:IMU, OTC:IUGNF)'s recent clinical and patent activities have drawn the attention of Roth Capital Partners, which has placed a “buy” recommendation on the clinical stage cancer-foc

Hanover Insurance Group, Inc. (THG) CEO John Roche on Q4 2021 Results - Earnings Call Transcript

Roche Holding's (RHHBY) CEO Severin Schwan on Full Year Results 2021 Results - Earnings Call Transcript

Roche Holdings AG''s (OTC: RHHBY ) FY21 sales increased 8% Y/Y (9% on a constant currency basis) to CHF 62.8 billion . Core operating profit gained 2% to CHF 21.9 billion. Core EPS - diluted increased 3% to CHF 19.81. Pharmaceuticals Division sales increased 1% (constant currency 3%) to CHF 45.04 billion on strong demand for newly launched medicines more than offsets impact of biosimilars. The Company saw earnings edge higher in 2021 Full story available on Benzinga.com

Roche (RHHBY) performance in the fourth quarter and 2021 was encouraging, driven by demand for COVID-19 tests and recovery in pharma sales. However, sales are expected to slow down in 2022.

Roche (RHHBY) ADRs are trading ~2% lower in the pre-market after the Swiss drugmaker warned that sales of its COVID-19 medicines and diagnostics could decline by CHF 2B CHF 5B in

Roche Holdings AG's RHHBY FY21 sales increased 8% Y/Y (9% on a constant currency basis) to CHF 62.8 billion. Thousands of new traders are learning the ins and outs on how to find profitable trades e

Roche Holding (RHHBY): FY Non-GAAP EPS of CHF19.81 misses by CHF0.59.Revenue of CHF62.8B (+7.7% Y/Y) beats by CHF470M.Core operating profit CHF21.90B, estimate CHF22.94BIFRS

Roche CEO Severin Schwan discusses the Swiss pharmaceutical's full-year 2021 earnings and the impact of the omicron variant on sales of it's Covid-19 tests.

Swiss drugmaker Roche said sales growth would slow this year as it braces for less demand for its COVID-19 medicines and diagnostics.

Roche Holding (OTCQX:RHHBY) is scheduled to announce FY earnings results on Thursday, February 3rd, before market open.The consensus EPS Estimate is $2.82 (-85.3% Y/Y) and the

Veteran strategist David Roche warns the recent volatility could be pointing toward a bear market, rather than a temporary speed bump in a continued bull run.

Pfizer (PFE) announced the appointment of Dr. William Pao as the companys Executive Vice President and Chief Development Officer effective March 22

Key Events This Week: ECB, BOE, Payrolls, Euro CPI And Earnings Galore It''s a relatively busy week with several key central bank announcements, notably from the ECB and BOE, as well as European CPI updates and the US payrolls report on Friday. Starting with the ECB, Deutsche Bank economists now expect a policy rate liftoff in December 2022 of 25bps, a view apparently shared by the market this morning. Theyre also anticipating a faster pace of tightening, with 25bp hikes in the deposit rate per quarter from December 2022, until rates reach +0.5% in September 2023. In terms of what it means for this February meeting, they write in their preview that they expect the slow, step-by-step pivot to exit will continue. Their view is that President Lagarde will reiterate the ECBs capacity to act once the inflation criteria in the rates guidance are met, whilst at the same time differentiating the needs of the Euro Area from the US. The other central bank decision that day is from the Bank of England, where expectations are for the BoE to follow up their December rate hike with another 25bps increase, taking the Bank Rate to 0.5%.

Roche Holding AG (RHHBY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.